Acute ICU Resuscitation of Severely Injured Trauma Patients: Do We Need a New Strategy?

Background Unlike recent advances in blood product resuscitation, crystalloid (IVF) use after ICU admission in hemorrhagic shock has received less attention and current recommendations are based on limited evidence. To address this knowledge gap, we aimed to determine associations between IVF administration during acute ICU resuscitation and outcomes. We hypothesized that larger IVF volumes are associated with worse outcomes. Methods We linked our trauma registry with EHR data (2012-2015) to identify adults with initial lactate ≥4 mmol/L and documented lactate normalization (≤ 2 mmol/L) - excluding those with isolated head AIS ≥ 3. We focused on the period from ICU admission to lactate normalization, analyzing duration, volume of IVF, and proportion of volume as one-liter boluses. We used linear regression to determine associations with ICU length of stay and duration of mechanical ventilation in survivors, and logistic regression to identify associations with AKI and home discharge while adjusting for important covariates. Results We included 337 subjects. Median time to lactate normalization was 15 hours (IQR [7, 25]) and median IVF volume was 3.7 L (IQR [1.5, 6.4]). The four-fold difference between the upper and lower quartiles of both duration and volume remained after stratifying by injury severity. Hourly volumes tapered over time, but persistently aggregated at 0.5 and 1 L, with 167 subjects receiving at least one 0.5 L bolus over 6 hours after ICU admission. Administration of larger volumes was associated with longer ICU length of stay and duration of mechanical ventilation, as well as AKI. Conclusions There is substantial variation in volume administered during acute ICU resuscitation, both absolutely and temporally, despite accounting for injury severity. Administration of larger volumes during acute ICU resuscitation is associated with worse outcomes. There is an opportunity to improve outcomes by further investigating and standardizing this important phase of care. Level of evidence IV. Study type Therapeutic/Care Management.